Skip to main content
Start of content

HESA Committee Meeting

Notices of Meeting include information about the subject matter to be examined by the committee and date, time and place of the meeting, as well as a list of any witnesses scheduled to appear. The Evidence is the edited and revised transcript of what is said before a committee. The Minutes of Proceedings are the official record of the business conducted by the committee at a sitting.

For an advanced search, use Publication Search tool.

If you have any questions or comments regarding the accessibility of this publication, please contact us at accessible@parl.gc.ca.

Previous day publication Next day publication
MINUTES OF PROCEEDINGS
 
Meeting No. 47
 
Tuesday, October 4, 2005
 

The Standing Committee on Health met at 9:10 a.m. this day, in Room 237-C, Centre Block, the Chair, Bonnie Brown, presiding.

 

Members of the Committee present: Bonnie Brown, Colin Carrie, Hon. Brenda Chamberlain, Jean Crowder, Nicole Demers, Ruby Dhalla, Steven John Fletcher, James Lunney, Rob Merrifield, Michael John Savage and Hon. Robert Thibault.

 

Acting Members present: Hon. Larry Bagnell for Ruby Dhalla, Marcel Gagnon for Réal Ménard and Mark Warawa for Steven John Fletcher.

 

In attendance: Library of Parliament: Nancy Miller Chenier, Analyst; Sonya Norris, Analyst.

 

Witnesses: Department of Health: Omer Boudreau, Director General, Therapeutic Products Directorate, Health Products and Food Branch; Philip Waddington, Director general, Natural Health Products Directorate, Health Products and Food Branch.

 
Pursuant to Standing Order 108(2) and the motion adopted by the Committee on Tuesday, October 4, 2005, the Committee commenced its study of the Canadian Strategy for Cancer Control.
 

Steven John Fletcher moved, — That the Standing Committee on Health, in recognition of the recommendations of major cancer groups in Canada and the motion passed by the House of Commons on June 7th, 2005, urge the government to implement and financially support the Canadian Strategy for Cancer Control.

Debate arose thereon.

 

Robert Thibault proposed to move — That the motion be amended by replacing the word “ Control.” with the words “ Control; and that the Chair of the Standing Committee on Health write a letter to the Chair of the Standing Committee on Finance outlining the importance of the strategy to the Standing Committee on Health, its value to the health of Canadians, and to urge that the Finance Committee take this into consideration during pre-budget consultation that are currently ongoing.”.

 

The Chair ruled the proposed amendment inadmissible as it introduced a new proposition that should be moved as a substantive motion, as provided on page 453 of House of Commons Procedure and Practice.

 

Marcel Gagnon moved, — That the motion be amended by replacing the words “implement and financially support” with the words “give financial support to the provinces for the implementation of”.

 

After debate, the question was put on the amendment of Marcel Gagnon and it was negatived, by a show of hands: YEAS: 2; NAYS: 9.

 

After debate, the question was put on the motion and it was agreed to, by a show of hands: YEAS: 9; NAYS: 2.

 
The Committee proceeded to the consideration of matters related to Committee business.
 

James Lunney moved, — That the Standing Committee on Health have officials from Health Canada and the Canadian Institutes for Health Research appear before it to explain the process and justification for contracts granted to the Earnscliffe Group for services rendered.

 

After debate, by unanimous consent, the motion was withdrawn.

 
Pursuant to Standing Order 108(2) and the motion adopted by the Committee on Thursday, May 19, 2005, the Committee resumed its study on silicone gel-filled breast implants.
 

Jean Crowder moved, — Whereas, the Expert Advisory Panel on Silicone Breast Implants heard three days of testimony from two manufacturers of implants, and;

Whereas, the Expert Advisory Panel heard only two and a half hours of testimony divided between forty witnesses during the public forum;

Be it resolved that the Standing Committee on Health study the issue of silicone breast implants and invite members of the public who appeared at the public forum to give a more detailed account of their evidence.

Debate arose thereon.

 

It was agreed, — That consideration of the motion be postponed until the next scheduled meeting of the Committee on Thursday, Otober 6, 2005.

 

Jean Crowder moved, — That, in light of the established conflicts of interest of certain members of the Scientific Advisory Panel who have worked directly and have been paid to promote silicone implants, by either of the two private sector implant manufacturers during US Food and Drug Administration hearings on the safety of silicone implants, the Standing Committee on Health urge the Minister of Health to immediately remove these persons from their position on the Panel.

Debate arose thereon.

 

It was agreed, — That consideration of the motion be postponed until the next scheduled meeting of the Committee on Thursday, Otober 6, 2005.

 
Pursuant to the Order of Reference of Wednesday, March 9, 2005, the Committee resumed consideration of Bill C-420, An Act to amend the Food and Drugs Act.
 

The witnesses made statements and answered questions.

 

At 11:12 a.m., the Committee adjourned to the call of the Chair.

 



Carmen DePape
Clerk of the Committee

 
 
2005/10/11 3:39 p.m.